Edition:
India

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

43.11USD
20 Jul 2018
Change (% chg)

$-1.00 (-2.27%)
Prev Close
$44.11
Open
$44.11
Day's High
$44.13
Day's Low
$41.50
Volume
53,322
Avg. Vol
108,428
52-wk High
$54.51
52-wk Low
$6.83

Summary

Name Age Since Current Position

Andrey Zarur

Chairman of the Board, Co-Founder

Martin Freed

57 2018 President, Director

Ilan Ganot

Chief Executive Officer, Co-Founder, Director

Alvaro Amorrortu

Chief Operating Officer

Jorge Quiroz

Chief Medical Officer

Biographies

Name Description

Andrey Zarur

Dr. Andrey J. Zarur, Ph.D. is Chairman of the Board, Co-Founder of the Company. Zarur is Co-Founder of the Comapny. He has been active in early stage life sciences companies for more than 20 years, and has participated in the creation of more than a dozen companies in the healthcare and clean energy sectors. He is also Chairman, CEO and Founder of GreenLight Biosciences and a partner at Kodiak Venture Partners, a venture capital firm specializing in the formation of early stage information and life technology investments. Prior to joining Kodiak Venture Partners, he was founder and CEO of BioProcessors, which was sold to Seahorse Biosciences in 2007. In addition to BioProcessors, he has led four life science companies from inception to exit. Dr. Zarur is also a co-founder and chairman of the board for Lumicell, and chairman of the board for Allegro Diagnostics. Dr. Zarur was named a Young Global Leader of the World Economic Forum in 2005. He is an Overseer of the Museum of Science in Boston and a Senior Lecturer at the Massachusetts Institute of Technology (MIT) Sloan School of Management. Dr. Zarur holds Masters of Science degrees and a Ph.D. in Chemical Engineering from MIT and undergraduate degrees from the National University of Mexico. Dr. Zarur is the author of several peer-reviewed articles and holds close to 100 provisional and issued patents.

Martin Freed

Dr. Martin I. Freed is President, Director of the company. He has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015. He co-founded and served as chief medical officer of Civitas Therapeutics, Inc. from December 2010 to October 2014 (acquired by Acorda Therapeutics, Inc. (“Acorda”)), and as senior vice president, clinical development of Acorda from October 2014 through January 2015. In addition, Dr. Freed has served as chief medical officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology and development strategy and preclinical development for multiple pharmaceutical companies throughout his career. These companies include Avila Therapeutics, Inc., Taligen Therapeutics, Inc., Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb) and Vitae Pharmaceuticals, Inc. Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals or SmithKline Beecham, where he served numerous roles including vice president, clinical development and medical affairs in the metabolism therapeutic area. Dr. Freed currently serves on the board of directors of Dicerna Pharmaceuticals, Inc. and Sojournix, Inc., and previously served on the board of directors of InteKrin Therapeutics Inc. from 2007 to 2010. He has authored over 100 publications or presentations. Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital. A Fellow of the American College of Physicians, Dr. Freed received his B.S. with distinction in biology from the University of Delaware and M.D. from Pennsylvania State University’s College of Medicine.

Ilan Ganot

Mr. Ilan Ganot is Chief Executive Officer, Co-Founder, Director of the Company. He started Solid in 2013 to find treatments, and potentially a cure, for Duchenne muscular dystrophy, a disease that afflicts his son Eytani. Prior to starting Solid, Mr. Ganot was an investment banker at JPMorgan Chase in London, specializing in hedge fund driven equities business for the firm. Mr. Ganot also worked at Nomura Securities in London, Hong Kong and New York, where he managed relationships with investors and clients of the firm. Prior to Nomura, Mr. Ganot was a senior salesperson for Lehman Brothers’ European Equities business. Mr. Ganot embarked on a banking career after practicing law at the Israeli law-firm, Haim Zadok & Co, where his focus was private equity law and mergers and acquisitions. Prior to practicing law, Mr. Ganot was division head at Vir-Tech, a laser engraving business, and a captain in the Israel Defense Forces. Mr. Ganot received his MBA from London Business school and holds law and business degrees from the IDC in Herzliya, Israel.

Alvaro Amorrortu

Mr. Alvaro Amorrortu is Chief Operating Officer of the Company. Prior to joining Solid Biosciences, Mr. Amorrortu spent more than a decade as a management consultant advising biopharmaceutical companies on a variety of strategic challenges, including overseeing large scale organizational transformations as well as designing strategies for assets and portfolios moving from early stages of development to commercial launch. His career as a strategist started at the Monitor Group, and then after a few years working for Inventiv Health (Campbell Alliance), moved to IMS Health. In addition, Mr. Amorrortu brings to Solid Biosciences, hands on experience managing operations. He held leadership positions in Bunge Group and Cargill subsidiaries, where he was responsible for running manufacturing facilities as well as complex engineering projects. Mr. Amorrortu received his M.B.A. with a major in Finance from The Wharton School and graduated from the Instituto Tecnologico de Buenos Aires, Argentina with an MS in Industrial Engineering.

Jorge Quiroz

Mr. Jorge A. Quiroz, M.D. is Chief Medical Officer of the Company. He provides leadership and clinical vision for the company, as well as being responsible for the clinical programs in patients with DMD. Prior to joining Solid, Dr. Quiroz served as the Head of Neurodevelopment & Psychiatry, Translational Medicine Neurosciences at Hoffmann-La Roche. A medical graduate from the Pontifical Catholic University of Chile and Board Certified Psychiatrist, he completed his medical training as a Research Fellow at the Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, at the National Institutes of Health in Bethesda, Maryland. He also holds a Master of Business Administration dual degree from Columbia University & London Business School. Dr. Quiroz received the NARSAD Young Investigator Award, the NCDEU New Investigator Award, the Fellows Award for Research Excellence, and the NIH Clinical Center Director’s Award, among other distinctions. He has designed and conducted numerous proof of concept studies, including studies in orphan designated indications, and has successfully filed New Drug Applications with the FDA during his tenure at Johnson & Johnson Pharmaceutical Research and Development and Hoffmann-La Roche. Dr. Quiroz has published over 45 peer reviewed scientific publications and book chapters in the fields of translational neurosciences and drug development.

Basic Compensation

Options Compensation